NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.

RTX builds a $271B backlog on defense demand and recovering air travel, but tariffs and supply-chain issues cloud growth.

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

May 19 (Reuters) - Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich ...

Sales of the problematic Amgen Inc. drug Tavneos resumed late last week in Japan with a new warning label after several ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ‌citing ⁠a lack of proven ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...